Selinexor
Overview
Selinexor is a selective inhibitor of nuclear export (SINE) compound used in cancer treatment. It works by blocking the export of tumor suppressor proteins from the nucleus, leading to their accumulation and activation in the nucleus, which induces apoptosis in cancer cells.
Patent & exclusivity (US)
Per the FDA Orange Book (6 approved US products), the latest listed US patent on Selinexor expires 14 Aug 2035 and exclusivity 18 Dec 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Selinexor? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.